Abstract: Methods for enhancing the efficacy, safety, and/or tolerability of a grass allergen-specific subcutaneous immunotherapy (SCIT) regimen in a subject having a grass allergy are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.
Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.
Type:
Grant
Filed:
October 21, 2019
Date of Patent:
November 15, 2022
Assignee:
Altor Bioscience, LLC
Inventors:
Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-Ping Han
Abstract: Embodiments of the present disclosure relate generally to the treatment of cancer involving activation of the tumor necrosis factor-related apoptosis inducing ligand receptor (TRAILR) pathway. In particular, the present disclosure provides compositions and methods for the identification of genes conferring TRAIL resistance, and the development of rational drug combinations targeting these genes. The therapeutic drug combinations of the present disclosure function synergistically to sensitize cancer cells to TRAIL-resistant cancers.
Abstract: Based on the identification of IL-33 as an exacerbating factor in endometriosis and adenomyosis uteri, a therapeutic agent for endometriosis and adenomyosis uteri has an IL-33 antagonist, which is capable of inhibiting the function of IL-33. The IL-33 antagonist is useful for treating, preventing or alleviating endometriosis and uterine adenomyosis uteri.
Type:
Grant
Filed:
August 31, 2018
Date of Patent:
November 8, 2022
Assignees:
MITSUBISHI TANABE PHARMA CORPORATION, HYOGO COLLEGE OF MEDICINE
Inventors:
Tomohiro Yoshimoto, Joseph M. Palumbo, Violetta I. Stone, Toru Kato, Koubun Yasuda
Abstract: A pharmaceutical composition comprising at least one antibody and at least one mesenchymal stromal cell-derived protein, use of the pharmaceutical composition for treating immunological diseases, for example alloimmune and autoimmune diseases, and use of the pharmaceutical composition for immunomodulation.
Type:
Grant
Filed:
August 18, 2017
Date of Patent:
November 8, 2022
Assignees:
Singapore Health Services Pte Ltd, Singapore General Hospital
Inventors:
Xiubo Fan, William Ying Khee Hwang, Hsiu Ling Low, Julian Thumboo, Chin Teck Ng
Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.
Type:
Grant
Filed:
May 30, 2019
Date of Patent:
November 8, 2022
Assignee:
Novartis AG
Inventors:
Aida Abujoub, John Blankenship, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Haihui Lu
Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology. The present invention relates to an anti-CTLA4 antibody, pharmaceutical composition and use thereof. The anti-CTLA4 antibody of the present invention can specifically bind CTLA4, and can very effectively block the binding of CLTA4 to B7.
Abstract: The inventors have developed a metastatic 4T1 breast tumor model in BALB/c mice. They have shown that the vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher anti-tumoral response against breast cancer and inhibits metastasis development. They established that these responses are achieved only by the addition of valproic acid in the therapeutic regimen in comparison to the use ESCs or iPSCs alone. Thus, the inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to i) a population of pluripotent cells and ii) a compound selected from a group which activates MHC expression, as a combined preparation for use in a method for treating a subject suffering from a cancer, comprising a step of administering simultaneously, separately or sequentially to said subject a therapeutically amount thereof.
Type:
Grant
Filed:
May 24, 2017
Date of Patent:
October 4, 2022
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITE PARIS-SACLAY, UNIVERSITE PARIS CITE
Inventors:
Frank Griscelli, Ali Turhan, Annelise Bennaceur Griscelli
Abstract: This document relates to methods and materials for treating a mammal having an autoimmune disease. For example, materials and methods for producing a T cell comprising a FOXP3 polypeptide and one or more transcription factors are provided herein. Methods and materials for treating a mammal having an autoimmune disease comprising administering to a mammal having an autoimmune disease an effective amount of a T cell are also provided herein.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
September 20, 2022
Assignee:
Kyverna Therapeutics, Inc.
Inventors:
Ashley Mahne, John Lee, Lih-Yun Hsu, Jeffrey Greve
Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.
Type:
Grant
Filed:
March 7, 2016
Date of Patent:
September 20, 2022
Assignees:
PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, PHARMA FOODS INTERNATIONAL CO., LTD.
Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
Type:
Grant
Filed:
February 26, 2020
Date of Patent:
September 20, 2022
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subject an agent that blocks PD-L1 and TGF-beta pathways, thereby inhibiting a malignancy associated with HPV in the subject.
Type:
Grant
Filed:
May 8, 2018
Date of Patent:
September 13, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Julius Y. Strauss, James L. Gulley, Christian S. Hinrichs
Abstract: The present invention relates to methods, kits and compositions for expansion of embryonic hematopoietic stem cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGF? pathway. Also provided herein are methods for expanding embryonic hematopoietic stem cells using kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGF? pathway. The embryonic hematopoietic stem cells expanded using the disclosed kits, compositions and methods include cells derived from an embryo (e.g., aorta-gonad-mesonephros region of the embryo), embryonic stem cells, induced pluripotent stem cells, or reprogrammed cells of other types.
Abstract: The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.
Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Type:
Grant
Filed:
April 30, 2020
Date of Patent:
September 13, 2022
Assignees:
Prometheus Biosciences, Inc., Cedars-Sinai Medical Center
Inventors:
Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
Abstract: The present invention is based, in part, on the discovery of monoclonal antibodies, and antigen-binding fragments thereof, that specifically bind to MICA/B ?3 domain, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
Type:
Grant
Filed:
May 22, 2018
Date of Patent:
August 23, 2022
Assignee:
DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
Lucas Ferrari de Andrade, Kai W. Wucherpfennig
Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.
Type:
Grant
Filed:
July 9, 2019
Date of Patent:
August 2, 2022
Assignees:
Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
Inventors:
Xiao Min Schebye, Diana Yuhui Chen, Andrew Rankin, Xiaodi Deng, Joseph Toth, Linda Liang, Michelle Minhua Han, Christine Bee, Hong-An Truong, Mark J. Selby, Nils Lonberg, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Alan J. Korman
Abstract: Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds of the eye.
Type:
Grant
Filed:
October 31, 2019
Date of Patent:
August 2, 2022
Assignee:
COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
Inventors:
Steven Dow, Kathryn Wotman, Lyndah Chow
Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
Type:
Grant
Filed:
September 12, 2018
Date of Patent:
August 2, 2022
Assignee:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors:
Sanjay Khandekar, Patrick Mayes, Joanna Opalinska